Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A9 | P48067 | 3/20 | 0.51 |
| ▸ | RIPK1 | Q13546 | 3/20 | 0.47 |
| ▸ | DRD4 | P21917 | 5/20 | 0.45 |
| ▸ | DRD2 | P14416 | 4/20 | 0.45 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.40 |
| ▸ | CCNC | P24863 | 1/20 | 0.40 |
| ▸ | CDK8 | P49336 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4160820 | 0.88 | SLC6A9 (0.48) | SLC6A9RIPK1DRD4DRD2MEN1 | |
| SCHEMBL4167781 | 0.81 | RIPK1 (0.45) | RIPK1DRD4DRD2MAPKAPK2L3MBTL1 | |
| SCHEMBL4167779 | 0.81 | RIPK1 (0.45) | RIPK1DRD4DRD2MAPKAPK2L3MBTL1 | |
| SCHEMBL27839601 | 0.79 | SLC6A9 (0.60) | SLC6A9L3MBTL1MEN1KMT2AALDH1A1 | |
| SCHEMBL25326556 | 0.78 | RIPK1 (0.42) | RIPK1MEN1KMT2AALDH1A1LMNA | |
| SCHEMBL18701971 | 0.76 | RIPK1 (0.72) | RIPK1CCNCCDK8 | |
| SCHEMBL25917422 | 0.75 | NR1H2 (0.43) | RIPK1ALDH1A1LMNAMAPTHDAC4 | |
| SCHEMBL4168263 | 0.74 | NOTUM (0.44) | RIPK1MEN1KMT2ALMNAMAPK1 | |
| SCHEMBL4166204 | 0.73 | NR1H2 (0.42) | RIPK1DRD4DRD2MEN1KMT2A | |
| SCHEMBL18701796 | 0.72 | LMNA (0.63) | DRD4DRD2L3MBTL1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090221582-A1 | Piperazine Derivatives And Their Use In Therapy | VERNALIS (R&D) (GB) | 2009-09-03 | — | — | US | disclosed |
| EP-1960391-A1 | PIPERAZINE DERIVATIVES AND THEIR USE IN THERAPY | Vernalis (R&D) Limited (GB) | 2008-08-27 | — | — | EP | disclosed |
| WO-2007057687-A1 | PIPERAZINE DERIVATIVES AND THEIR USE IN THERAPY | VERNALIS (R & D) LIMITED (GB) | 2007-05-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090221582-A1 | Piperazine Derivatives And Their Use In Therapy | CNR2, CNR1, ALK | SLC6A9 1991/4885RIPK1 3742/4885DRD4 1007/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.